Intralesional ultrasound-guided combined treatment with triamcinolone plus lincomycin in hidradenitis suppurativa: A pilot study.
acne inversa
antibiotic
corticosteroid
hidradenitis suppurativa
intralesional treatment
lincomycin
triamcinolone
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
06
05
2020
revised:
25
05
2020
accepted:
19
06
2020
pubmed:
27
6
2020
medline:
15
5
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic, inflammatory, disease of the hair follicle. Intralesional corticosteroid treatment in HS patients has been reported, and while several data described this route of administration as an efficient delivery system, its efficacy is still debated. The aim of this study was to explore the clinical efficacy and the effect on quality of life (QoL) of an innovative intralesional treatment in HS patients. This was an interventional prospective study. The treatment consisted of two intralesional ultrasound-guided injections of triamcinolone plus lincomycin, at baseline and after 2 weeks. Lesions and QoL were evaluated at baseline and at 4 weeks following intralesional therapy. All clinical variables of 36 HS patients significantly improved after 4 weeks. Mean values of the visual analog scale (VAS) pain decreased from 4.6 to 1.5, P = .027. The Bodily Pain (BP) scale of the Short-Form Health Survey (SF-36) significantly improved from 36.2 at baseline to 53.9 at 4-week follow-up (P < .001). On a scale from 0 to 10, over 90% of the patients gave a satisfaction score of 8 or more. This combination of corticosteroids and antibiotics delivered intralesionally seems to be effective, as it improved both patient- and physician-reported outcomes.
Substances chimiques
Triamcinolone
1ZK20VI6TY
Lincomycin
BOD072YW0F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13901Subventions
Organisme : "Progetto Ricerca Corrente - 2020" of the Italian Ministry of Health, Rome, Italy
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619-644.
Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017;318:2019-2032.
Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831-839.
Hidradenitis suppurativa. Nat Rev Dis Primers 2020; 6:19. https://doi.org/10.1038/s41572-020-0159-z.
Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91:328-332.
Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, Hamzavi I. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology. 2020;14:1-20.
Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81:91-101.
National Cancer Institute, 2016. PubChem BioAssay database; CID 31307 NCI. https://pubchem.ncbi.nlm.nih.gov/compound/triamcinolone#section=Top. Accessed April 5, 2016.
Jemec GBR, Leyden J. Hidradenitis suppurativa. Berlin: Springer; 2006.
Riis PT, Boer J, Prens EP, et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol. 2016;75:1151-1155.
Maini P, Los Rios C, Gooderham M. Intralesional corticosteroid injections as a treatment option for acute lesions in patients diagnosed with hidradenitis suppurativa. J Am Acad Dermatol. 2015;72:AB51.
Álvarez P, García-Martínez FJ, Poveda I, Pascual JC. Intralesional triamcinolone for fistulous tracts in hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up. Dermatology. 2019;29:1-6.
García-Martínez FJ, Vilarrasa Rull E, Salgado-Boquete L, et al. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. J Dermatolog Treat. 2019;29:1-5. https://doi.org/10.1080/09546634.2019.1655524 [Epub ahead of print].
Fajgenbaum K, Crouse L, Dong L, Zeng D, Sayed C. Intralesional triamcinolone may not be beneficial for treating acute hidradenitis suppurativa lesions: a double-blind, randomized, placebo-controlled trial. Dermatol Surg. 2020;46(5):685-689.
Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigh R, Roenigh H, eds. Dermatologic Surgery. New York: Marcel Dekker; 1989:729-739.
Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61:51-57.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
Apolone G, Mosconi P. The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol. 1998;51:1025-1036.
Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol. 2006;126:1244-1250.
Bellantuono C, Fiorio R, Zanotelli R, Tansella M. Psychiatric screening in general practice in Italy. A validity study of the GHQ (general health questionnaire). Soc Psychiatry. 1987;22:113-117.
Goldberg D. The Detection of Psychiatric Illness by Questionnaire. London: Oxford University Press; 1972.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596-601.
Caposiena Caro RD, Cannizzaro MV, Botti E, et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound observations. J Am Acad Dermatol. 2019;80:1314-1321.
Bettoli V, Join-Lambert O, Nassif A. Antibiotic treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34:81-89.
Spízek J, Rezanka T. Lincomycin, clindamycin and their applications. Appl Microbiol Biotechnol. 2004;64:455-464.
Kanee B. Lincomycin in dermatologic practice. Can Med Assoc J. 1965;93:220-222.
Barranco VP, Minor DB, Doran CK. Letter: topically applied lincomycin for acne. Arch Dermatol. 1976;112:1469.
Sharma AD, Gupte PD, Sundaram M, et al. Topical lincomycin gel in acne vulgaris: a multicentric placebo controlled study. Indian J Dermatol Venereol Leprol. 2003;69:271-273.
Scheinfeld N. Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2013;19:1.
Friedman SJ, Butler DF, Pittelkow MR. Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. J Am Acad Dermatol. 1988;19:537-541.
Sampogna F, Tabolli S, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study. Br J Dermatol. 2007;157:508-513.